Haemonetics Corporation HAE
Haemonetics Corporation (NYSE: HAE) is a drug developer. Its lead program is marketed. Its next catalyst on record is NexSys PCS devices with Persona PLUS technology - CSL Plasma rollout: Complete rollout of devices to all CSL U.S. plasma collection centers (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: NexSys PCS devices with Persona PLUS technology - CSL Plasma rollout — Complete rollout of devices to all CSL U.S. plasma collection centers (2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.